Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on July 7, 2002, detailing an event that occurred on July 8, 2002. The primary focus of this filing is the issuance of a press release on July 8, 2002, which is included as an exhibit. While the content of the press release is not detailed within the 8-K itself, its issuance represents a material event for the company and its investors. Investors should note that this filing is primarily procedural, informing the market about the release of new information by Regeneron. The significance of this press release would depend entirely on its content, which is presumed to contain information relevant to the company's operations, pipeline, financial performance, or strategic initiatives. Shareholders and potential investors are advised to review the attached press release for specific details.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed a Form 8-K with the SEC on July 7, 2002.
- 2The report covers an event dated July 8, 2002.
- 3The core of the filing is the issuance of a press release on July 8, 2002.
- 4The press release is included as an exhibit to this 8-K filing.
- 5The filing's Item 5, 'Other Events,' specifically references the press release.
- 6The filing's Item 7(c) lists the press release as an exhibit.
- 7Stuart Kolinski, Vice President & General Counsel, signed the report on behalf of Regeneron.